Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis

BACKGROUND AND OBJECTIVES: GLPG1690 is an autotaxin inhibitor in development for the treatment of idiopathic pulmonary fibrosis. Several publications suggested a role of autotaxin in the control of disease-affected lung function and of lysophosphatidic acid in lung remodeling processes. The aim of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Taneja, Amit, Desrivot, Julie, Diderichsen, Paul Matthias, Blanqué, Roland, Allamasey, Lisa, Fagard, Liesbeth, Fieuw, Ann, Van der Aar, Ellen, Namour, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719325/
https://www.ncbi.nlm.nih.gov/pubmed/30953319
http://dx.doi.org/10.1007/s40262-019-00755-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719325/
https://www.ncbi.nlm.nih.gov/pubmed/30953319
http://dx.doi.org/10.1007/s40262-019-00755-3

Ejemplares similares